Prostatype Genomics AB manufactures, markets and sells the prognostic gene test Prostatype. The company is headquartered in Solna, Stockholm and currently employs 6 full-time employees. The company went IPO on 2020-11-03. The firm's business model and concept is to manufacture, market and sell the Prostatype Test System as one prognostic package consisting of the Prostatype RTqPCR kit, the patient database and the evaluation software and accessories P-score. The test is supposed to check the aggressiveness of the prostate cancer in order to help clinicians and patients to make correct treatment decisions. Prostatype analyzes the gene expression in cancer cells extracted from prostate tissue and gives, in combination with an advanced algorithm and data analysis, decision support for optimal treatment of individual patients once prostate cancer has been confirmed.
Follow-Up Questions
¿Quién es el CEO de Prostatype Genomics AB?
Fredrik Persson es el Chief Executive Officer de Prostatype Genomics AB, se unió a la empresa desde 2017.
¿Qué tal es el rendimiento del precio de la acción PGABF?
El precio actual de PGABF es de $0, ha decreased un 0% en el último día de negociación.
¿Cuáles son los temas de negocio principales o las industrias de Prostatype Genomics AB?
Prostatype Genomics AB pertenece a la industria Biotechnology y el sector es Health Care
¿Cuál es la capitalización bursátil de Prostatype Genomics AB?
La capitalización bursátil actual de Prostatype Genomics AB es $0
